Showing results (121-130 of 139) with videos related to
Sort By:
Pageof 14
Eclinicalmedicine|February 8, 2021
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, Shamia Hoque, Nancy Olivieri, et al.Antimicrobial Agents and Chemotherapy|November 17, 2023
Individual meropenem epithelial lining fluid and plasma PK/PD target attainmentRoxane Rohani, Paul R Yarnold, Marc H Scheetz, et al.Plos One|June 26, 2020
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemiaShamia Hoque, Brian J Chen, Martin W Schoen, et al.Plos One|August 1, 2019
Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactionsCharles L Bennett, Benjamin Schooley, Matthew A Taylor, et al.AIDS Patient Care and Stds|March 10, 2004
HIV-related pneumonia care in older patients hospitalized in the early HAART eraAshish Sureka, Jorge P Parada, Maria Deloria-Knoll, et al.Antimicrobial Agents and Chemotherapy|December 29, 2025
Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumoniaRyan Williamson, Marta Zurawska, Adrian Valadez, et al.Antimicrobial Agents and Chemotherapy|May 15, 2025
Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMOAdrian Valadez, Marta Zurawska, Emma Harlan, et al.Antimicrobial Agents and Chemotherapy|December 29, 2025
Pharmacokinetic-pharmacodynamic target attainment with continuous infusion piperacillin in patients admitted to the ICU with hospital-acquired pneumoniaMarta Zurawska, Adrian Valadez, Emma Harlan, et al.Journal of the American College of Cardiology|January 3, 2006
Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) projectJonathan R Nebeker, Renu Virmani, Charles L Bennett, et al.The Oncologist|February 15, 2021
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse ReactionsCharles L Bennett, Sumimasa Nagai, Andrew C Bennett, et al.Pageof 14